A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer
We want to determine the effects of Herceptin and to determine its efficacy in women with
HER-2 overexpressing advanced breast cancer. The end-points will include the comparison of
an array of histologic and molecular markers from sequential core biopsies of primary breast
cancers of patients receiving Herceptin.
The other aim of this study would be to determine clinical response to therapy with
Herceptin and Taxotere.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer
Mothaffar Rimawi, MD
Baylor Breast Center, Baylor College of Medicine
United States: Food and Drug Administration
|Baylor Breast Center||Houston, Texas 77030|